Abstract
Aims: This study concentrates on the relationship between antipsychotic drugs (APDs) and aortic calcification.Methods: All 56 patients with schizophrenia were divided into two groups according to aortic calcification index. APD equivalent dose was calculated via defined daily doses method.Results: In schizophrenia patients with higher aortic calcification index scores, APD equivalent doses were lower. APD equivalent dose was negatively related to aortic calcification index. Although equivalent APD dose in patients without olanzapine treatment was negatively related to aortic calcification index, it seems that equivalent APD dose did not associate with aortic calcification.Conclusion: Aortic calcification is negatively associated with APD dose in schizophrenia patients. Olanzapine seems to be vital to the relationship between aortic calcification and APD treatment.
Highlights
Severe mental illness has persistent procession, and schizophrenia causes serious disabilities to individuals worldwide [1]
We investigated schizophrenia patients to explore the relationship between Antipsychotic drugs (APDs) treatment and aortic calcification
All schizophrenia patients included in this project were divided into two groups according to their AoAC score
Summary
Severe mental illness has persistent procession, and schizophrenia causes serious disabilities to individuals worldwide [1]. Antipsychotic drugs (APDs) are essential in providing recovery opportunities for schizophrenia patients [2, 3]. Besides alleviating symptoms, APDs lead to adverse effects, especially elevating cardiovascular risks [4]. Several APDs have been proven to have metabolic effects, which would cause cardiovascular diseases [5]. Different APDs exert adverse side effects on the vascular system, based on their metabolic effects [7]. Olanzapine has been confirmed to result in metabolic syndromes and exert several adverse cardiovascular effects [8, 9]. The dose of APD is especially vital for all patients who underwent such a medication process [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
